Prospective, randomized multi-center, open label phase II study to determine the activity of a non chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabin-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced Non-Small-Lung-Cancer. MedDRA version: 14.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA vers
Conditions
Interventions
Trade Name: Tarceva
Product Name: Tarceva
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: erlotinib
CAS Number: 183319-69-9
Current Sponsor code: Ro 50-8231/OSI-774
Concentration unit: mg
Sponsors
Aktion Bronchialkarzinom e.V.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Histological confirmed Non-small cell lung cancer that can not be treated within a defined radiological field • Tumor stage IIIB (pleural effusion or pericardial effusion included) or IV • The following histological tumor types are eligible: - Adenocarcinoma (including adenocarcinomas with bronchioloalveolar differentiation) - Large Cell Carcinoma (including large cell carcinomas with neuroendocrine differentiation) - Mixed Cell Carcinoma without small cell fraction and without predominant squamous cell fraction ( 60 ml/min • Adequate plasmatic blood coagulation - INR = 1,5 and PTT = 1,5 x ULN • Normal cardiac function defined by LVEF > 49% (echocardiography) • Electrocardiogram without significant signs of cardiac arrhythmias • Provision of informed consent according to local regulatory requirements prior to any protocol specific treatment. • Measurable lesion according to RECIST-Criteria's • Negative pregnancy test for women of childbearing potential unless they are postmenopausal at baseline. (Postmenopausal women must have been amenorrheic at least for 12 months to be considered of non childbearing potential) • Women of child bearing potential to must be willing to use an acceptable method to avoid pregnancy at least one month before study start. Examples: oral contraceptives (sole application of oral contraceptives is not sufficient), diaphragm pessary, intrauterine device (spiral), condom plus diaphragm pessary plus spermicide. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Histologic confirmed squamous cell carcinoma • Pregnancy or lactation period • Tumor extension treatable with radiotherapy • Current clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT or MRI brain scan. • Evidence of tumor invading or abutting major blood vessels • Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of a CIS of the cervix or non-melanomatous skin cancer. Patients curatively treated and free of disease for at least 5 years will be discussed with the Principal Investigator (LKP) before inclusion. • Any previous chemotherapy within the last five years • Any radiotherapy with exception of the following situations: - concomitant small field radiotherapy in the case of solitary bone metastases or other solitary metastases - in case of large field radiotherapy or multi-radiation fields due to multiple bone metastases or other metastases. The application of study medication then must be delayed at least for 24 h (after last radiotherapy) - in case of radiotherapy of the primary tumor trial therapy can be employed if radiotherapy has ended at least 6 weeks ago and new tumor progression is clearly documented. • Treatment with an investigational new drug, currently or within the last 28 days, and/or participation in another clinical trial, currently or during the last 12 weeks, and/or previous participation in this study. • A history or presence of any CNS disorder or psychiatric disability judged by the Investigator to be clinically significant and/or interfering with compliance of oral drug intake • Patients with any clinically significant disease that in the opinion of the investigator is likely to put the patient at risk or to interfere with the evaluation of the patient's safety and of the study outcome. This includes, but is not limited to: - Any known significant ophthalmologic abnormalities of the surface of the eye (the use of contact lenses is not recommended). - Immediate need for therapeutic intervention (e.g.: upper inflow congestion or poststenotic pneumonia). - Clinically significant cardiac disease (e.g. right-sided heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months. - pleural effusion or pericardial effusion with the need for intervention • Uncontrolled hypertension • Non healing wound, ulcer or bone fracture • Fresh thrombosis under therapy with anticoagulants. • Hemorrhagic diathesis, Hemophilia A, Hemophilia B • Implantation of a central vein catheter (Prot-Catheter) within 24 h prior to application of study medication • Present hemoptysis of any CTC grade or history of hemoptysis of any CTC grade within 3 month prior to study start • Peritoneal carcinomatosis. • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to study start • Interstitial pneumonia or extensive or symptomatic interstitial fibrosis of the lung. • Pleural effusion or ascites, which cause respiratory compromise. • Any other active or uncontrolled infection • Organ allograft • History of a mental disease or condition such as to interfere with the patient's ability to understand the requirements of the study and the intake of study medication according to study protocol. • Inabili
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine the anti-tumor-activity of a non chemotherapy first line biological treatment with erlotinib and bevacizumab or chemotherapy plus bevacizumab in non-squamous advanced Non-Small Cell Lung Cancer. The main efficacy parameter is the progression free survival.;Secondary Objective: • Overall survival • Quality of life • Response rate • Explorative subgroup analyses • Molecular investigations ;Primary end point(s): All statistical methods are merely descriptive, no confirmatory analyses are planned. The primary endpoint, PFS (progression free survival), will be reported for each treatment group by Kaplan-Meier estimators with pointwise 95% confidence intervals. Additionally, a Cox regression model will be fitted to calculate a point estimator and its 95% percent confidence interval for the hazard ratio between groups. All secondary endpoints will be reported using adequate descriptive statistics. | — |
Countries
Germany
Outcome results
None listed